Introduction
Pregnancy presents a significant hemodynamic challenge, especially for women with coagulation problems. Rare coagulation factor disorders are defined as monogenic bleeding disorders caused by a deficiency in blood coagulation factors other than Hemophilia A, Hemophilia B, and von Willebrand disease, and thus include deficiencies in factors II, V, VII, XI, XII, XIII, as well as dysfibrinogenemia. Rare coagulation disorders account for 3 to 5 percent of all inherited bleeding diseases. Bleeding disorders such as von Willebrand disease (VWD), hemophilia, various coagulation factor deficits, platelet abnormalities, fibrinolysis defects, and connective tissue disorders affect both the mother and the fetus. Successful therapy of bleeding disorders in pregnant women necessitates not only a knowledge of bleeding disorders but also a grasp of when and how bleeding occurs during pregnancy. During a typical pregnancy with a healthy placenta, there is no bleeding. Bleeding happens during pregnancy when the normal uteroplacental interface is disrupted, after a miscarriage, an ectopic pregnancy, or when the placenta separates at the end of the pregnancy.
What Are Rare Bleeding Disorders?
Rare bleeding disorders include lack of fibrinogen, prothrombin, factor V, factor VII, factor X, factor XI, and factor XIII, as well as combination deficiency syndromes, factor V and VIII deficit, and vitamin K-dependent factor deficiency (factor II, VII, IX, X). They account for three to five percent of all hereditary coagulation disorders. Because of their rarity, information on pregnancy problems and management is scarce and primarily drawn. Fibrinogen and FXIII deficiencies have been firmly linked to an increased risk of recurrent miscarriage and placental abruption. Factor replacement is used to mitigate these hazards. However, the probability of miscarriage and antepartum problems is unclear in women with various bleeding disorders. Hemostatic problems in women with rare bleeding diseases appear to remain during pregnancy, particularly if the impairment is severe. As a result, women with these diseases are more likely to experience postpartum hemorrhage. The fetus may also be harmed, putting it at risk for bleeding issues. Specialized multidisciplinary management is required to reduce the risk of maternal and newborn problems and provide the best possible outcome.
What Are Perinatal Outcomes in Women With Rare Coagulation Disorders?
1. Defects of Fibrinogen
Fibrinogen is a big molecule with two identical halves, each consisting of three. Protein chains (alpha, beta, and gamma). Fibrinogen abnormalities include afibrinogenemia (absence of fibrinogen) and hypofibrinogenemia (low fibrinogen levels). A structurally abnormal fibrinogen dysfibrinogenemia. In practice, it can be difficult to identify between hypo- and dysfibrinogenemia. Mild forms are often underdiagnosed. Fibrinogen disorders exhibit severe bleeding symptoms. They are uncommon.
2. Prothrombin Deficiency
Factor II (FII) is a vitamin K-dependent carboxylase produced in the liver. It is a single-chain glycoprotein with four domains. FII deficiency is quite rare. Hypoprothrombinemia refers to a low level of a normal molecule (type 1), while hypoprothrombinemia is characterized by diminished activity. Antigen normal (type 2): a complete deficit may not be compatible.
3. Factor V Deficiency
Factor V is a big glycoprotein. Hepatocytes and megakaryocytes generate FV, which is encoded on chromosome 1. Platelets contain around 20 percent of circulating FV. FV insufficiency is rare, occurring in one in a million of the overall population.
4. Factor VII Deficiency
Factor VII (FVII) is a vitamin K-dependent glycoprotein encoded on chromosome 13. There is little association between the FVII level and a wide range of bloody manifestations. Mucous membrane menorrhagia and epistaxis are two examples of bleeding. Some patients have severe deficiencies. The combined loss of FV and FVIII. It is significant since it is the first clotting condition caused by gene abnormalities outside the body. Coagulation factor genes, as inheritance patterns suggested. The disorder is induced by abnormal transportation across the endoplasmic reticulum. Bleeding happens after surgery and dental procedures. Women may experience menorrhagia following extractions and postpartum hemorrhage.
5. Factor X Deficiency
FX deficiency results in severe hemorrhage. It poses a higher risk to the International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use during the neonatal era. So, where both parents are known to be heterozygous, a delivery management plan should be prepared and the infant monitored. Look closely for signs of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Humans. Menorrhagia is also rather prevalent in 50 percent of women. Joint hemorrhage may result in severe arthropathy. Preventive therapy for severe FX deficiency should be investigated.
6. Factor XI Deficiency
Women may experience menorrhagia and bleeding after childbirth. Individuals with severe deficiency (FXI < 10 IU/dL) experience modest symptoms. The tendency to bleed following surgery, particularly in areas with significant fibrinolytic potential, such as mouth, nose, and genitor-urinary tract. Spontaneous bleeding is unusual, and hemarthrosis is not a feature. The condition seldom manifests in the neonatal phase. However, bleeding may occur following circumcision.
7. Factor XII Deficiency: Factor XII (FXII) deficiency does not give rise to a bleeding disorder.
8. Factor XIII: FXIII deficiency is uncommon, affecting only one in every million people. Similar to other uncommon illnesses, heterozygotes are asymptomatic. Affected individuals experience excessive bleeding from the umbilical stump and are at risk for ICH, which can arise during the neonatal period. Extensive skin bruising and bleeding are patients who may have muscular pain and Joint bleeds. Pregnancy is frequently related to miscarriage unless prophylaxis is used.
What Is the Diagnosis of Rare Coagulation Disorders?
Rare Blood Disorder Diagnosis
Laboratory tests for inquiry and diagnosis might be impacted by collecting and processing procedures. Selection and implementation of the assays. A good venipuncture with free-flowing blood. It is vital to pull blood into the anticoagulant. Take care to fill the container correctly. Poor or painful venipuncture can result in tissue. Activation in the sample and false normal even in cases of severe coagulation disorders. Samples should be centrifuged immediately. Possible and either analyzed or frozen within 4 hours for collecting. Frozen samples should be quickly thawed for a test.
What Is the Management of Rare Coagulation Disorders?
Managing Pregnancy for Women With Rare Diseases:
Pregnancy in women with severe and uncommon diseases is best managed in an obstetric unit in a hospital. It includes a hemophilia center. If it is not possible, close collaboration between the obstetric unit and the hemophilia center is necessary. Effective communication between pediatricians, hematologists, and obstetricians is important to guarantee adequate inquiry and manage a potentially impacted newborn. Several of these severe illnesses are linked to a significant risk of intracranial hemorrhage (ICH) in their first week of life. Pediatricians and neonatologists must be aware of the increased risk of rare, severe coagulation abnormalities in offspring. Parents who are relatives. Bleeding should be investigated immediately, and then bleeding symptoms should be aggressively treated to increase the level of the missing coagulation factor. Inadequate or delayed therapy for ICH in newborns causes death or significant long-term disability. It is also vital to have appropriate ranges for factor levels used. In infants and children, most newborns have reduced coagulation factors due to hepatic immaturity and/or vitamin K insufficiency (which influences variables II, VII, IX, X, and XI) so that if there is any uncertainty, levels should be evaluated again after six months.
Conclusion
Rare coagulation disorders exhibit more variability than hemophilia, making diagnosis and treatment challenging and management. Be aware of the higher risk of these disorders in relevant populations. Groups will raise a higher level of suspicion, resulting in an earlier detection of profoundly impacted infants who are in danger of severe bleeding, particularly ICH.
